Immunogenicity and tolerability of yellow fever vaccination in 23french HIV-infected patients

Current HIV Research

Volumn 8, Issue 6, 2010, Pages 461-466

  Pistone, Thierry ^a   Verdière, Claire Hélène ^a   Receveur, Marie Catherine ^a   Ezzedine, Khaled ^b   Lafon, Marie Edith ^a   Malvy, Denis ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Human immunodeficiency virus; Vaccination; Yellow fever

Indexed keywords

STAMARIL; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; ASTHENIA; CD4+ T LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; FEVER; FRANCE; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; IMMUNOLOGICAL TOLERANCE; MALE; NONHUMAN; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SEROLOGY; TREATMENT RESPONSE; VIRUS LOAD; YELLOW FEVER;

EID: 78249234150     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210793499277     Document Type: Article

References (12)

1. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981; 59: 895-900.
2. Gershman M, Schroeder B, Staples J. Yellow fever. Health Information for International Travel. 2009. Available at: http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/yellow-fever.aspx. Accessed November 5, 2009.
3. Fitzner J, Coulibaly D, Kouadio DE, et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine 2004; 23: 156-62.
4. Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001; 358: 91-7.
5. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001; 358: 121-2.
6. Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001; 358: 98-104.
7. Centers for Disease Control and Prevention (CDC). Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002; 51: 989-993.
8. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002; 85: 131-4.
9. Sibailly TS, Wiktor SZ, Tsai TF, et al. Poor antibody response to yellow fever vaccination in children infected with humanimmunodeficiency virus type 1. Pediatr Infect Dis J 1997; 16: 1177-9.
10. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 2009; 48: 659-66.
11. Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Le Bras M. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin Infect Dis 2000; 31: E7-8.
12. Tattevin P, Depatureaux AG, Chapplain JM, et al. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 2004; 18: 825-7.